NCT Number: NCT04519957
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).
Looking for future studies?
Notify Me18 year–55 year
All sexes
Observational
National Institute of Mental Health Czech Republic, Klecany, Czechia
In this present study (COMP 004), the aim is to follow up participants from COMP 001 and COMP 003 in a long-term follow up study, with both remote and digital assessments, to explore the long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25 mg) administered to patients with TRD as a monotherapy in COMP 001 and 25 mg psilocybin administered as an adjunct to an SSRI in COMP 003. Patients previously treated in COMP001 will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will be followed for approximately 49 weeks giving a total follow up period of 52 weeks from psilocybin dosing.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Signed ICF Each participant having completed the final study visit of either COMP 001 or COMP 003 Ability to complete all protocol required assessment tools (including having access to the internet in order to complete the digital assessments) without any assistance or alteration to the copyrighted assessments, and to comply with all study visits
Exclusion criteria
Subject has any condition, for which in the opinion of the investigator, participation would not be in the interest of the subject eg participation could compromise the wellbeing of the participant or prevent, limit, or confound the protocol-specified assessments
Time frame: up to 52 weeks
Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)
Time frame: Up to 52 weeks
Montgomery Asberg Depression Rating Scale (MADRS)
Time frame: up to 52 weeks
Work and Social Adjustment Scale (WSAS) score change from Baseline of the prior study
Time frame: Up to 52 weeks
Sheehan Disability Scale (SDS) score change from Baseline of the prior study
Time frame: Up to 52 weeks
Incidence and severity of Adverse Events (AEs) and Seroius Adverse Events (SAEs)
COMPASS Pathways
Industry
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03680781
Depressive Disorder, Depressive Disorder, Treatment-Resistant
Palo Alto, California, United States
View Trial DetailsNCT05913401
Depressive Disorder, Depressive Disorder, Treatment-Resistant
Providence, Rhode Island, United States
View Trial DetailsNCT06230757
Anhedonia, Depressive Disorder
Aurora, Colorado, United States
View Trial DetailsNCT03191058
Behavior, Behavioral Symptoms
San Diego, California, United States
View Trial Details